bovin
respiratori
diseas
brd
major
sourc
econom
loss
within
agricultur
industri
vaccin
brdassoci
virus
offer
complet
immun
protect
vaccin
failur
anim
present
potenti
rout
diseas
spread
serolog
differenti
infect
vaccin
anim
diva
possibl
use
antigendelet
vaccin
viru
outbreak
diva
respons
mask
wildtyp
viru
prevent
accur
serodiagnosi
previou
work
author
establish
potenti
metabolom
profil
reveal
metabolit
associ
system
immun
respons
vaccin
current
studi
build
work
demonstr
first
time
potenti
use
plasma
metabolit
profil
differenti
vaccin
nonvaccin
anim
follow
infectionchalleng
male
holstein
friesian
calv
intranas
vaccin
pfizer
rispov
subsequ
challeng
bovin
parainfluenza
viru
via
nasal
inocul
metabolom
plasma
profil
reveal
viral
challeng
led
shift
acquir
plasma
metabolit
profil
day
pi
metabolit
identifi
whose
peak
intens
significantli
differ
follow
viral
challeng
depend
vaccin
statu
elev
level
biliverdin
bilirubin
decreas
acid
nonvaccin
anim
day
pi
may
associ
increas
oxid
stress
reactiv
oxygen
scaveng
period
peak
viru
titr
latter
stage
infect
increas
level
n
glycin
lysophosphatidycholin
decreas
enterolacton
nonvaccin
anim
may
reflect
suppress
innat
immun
respons
mechan
progress
adapt
immun
respons
level
hexahydrohippur
also
shown
significantli
elev
nonvaccin
anim
day
pi
find
demonstr
potenti
metabolom
profil
identifi
plasma
marker
employ
diseas
diagnost
applic
differenti
identifi
infect
nonvaccin
anim
diseas
outbreak
provid
greater
inform
health
statu
infect
anim
introduct
bovin
respiratori
diseas
brd
multifactori
diseas
characterist
viralbacteri
synergist
infect
predisposit
environment
stressor
diseas
constitut
major
sourc
econom
loss
mortal
clinic
diseas
associ
treatment
long
last
reduc
growth
perform
infect
young
stock
annual
cost
brd
estim
usa
prevent
measur
contribut
vaccin
commonli
use
control
brd
viral
pathogen
despit
season
vaccin
anim
becom
infect
new
outbreak
maintain
infect
within
popul
viral
pathogen
associ
brd
bovin
parainfluenza
viru
bovin
respiratori
syncyti
viru
bovin
viral
diarrhoea
viru
bovin
herp
impair
immun
respons
infect
anim
damag
respiratori
tract
allow
establish
secondari
infect
may
develop
bacteri
pneumonia
howev
vaccin
anim
success
clear
viral
infect
faster
nonvaccin
anim
immun
memori
respons
reduc
associ
viral
tissu
damag
impair
immun
function
prevent
establish
secondari
bacteri
mycoplasma
infect
diseas
outbreak
identif
unvaccin
anim
earli
stage
infect
could
provid
window
effect
treatment
facilit
remov
anim
pose
greater
risk
becom
infect
transmit
infect
suscept
juvenil
stock
furthermor
halt
viral
diseas
progress
sever
costli
secondari
bacteri
infect
identif
vaccin
failur
anim
infect
outbreak
would
reduc
level
antibiot
use
agricultur
industri
definit
method
success
identifi
vaccin
anim
presenc
activ
viral
infect
determin
rate
viral
shed
viru
isol
cytokineinterleukin
profil
viru
neutral
assay
type
analysi
requir
repeat
sampl
period
seroconvers
expens
compar
serolog
base
elisa
therefor
routin
employ
endem
viral
infect
outbreak
differenti
infect
vaccin
anim
diva
marker
vaccin
eg
modifi
wild
type
viru
gene
delet
result
absenc
particular
diagnost
antigen
employ
differenti
vaccin
antibodi
respons
wild
type
viru
companion
serolog
base
test
reli
seroconvers
upon
exposur
wild
type
viru
antibodi
respons
diva
vaccin
mask
wild
type
viru
vaccin
diva
function
often
limit
larg
virus
increas
potenti
gene
delet
remov
redund
express
antigen
therefor
virus
small
genom
paramyxovirus
eg
bovin
respiratori
syncyti
viru
brd
complex
gene
delet
neutral
antigen
may
reduc
vaccin
efficaci
altern
approach
requir
provid
diva
function
one
approach
design
molecular
diva
vaccin
contain
marker
nucleotid
sequenc
differ
wild
type
viru
employ
combin
pcrbase
molecular
diagnost
differenti
vaccin
wild
viru
strain
success
differenti
vaccin
nonvaccin
anim
use
techniqu
requir
concurr
vaccin
infect
narrow
diagnost
window
postinfect
detect
diva
vaccin
viral
genet
materi
furthermor
detect
vaccin
genet
materi
demonstr
exposur
vaccin
success
gener
immun
protect
limit
function
assess
herd
level
immun
consequ
clear
need
altern
diagnost
method
assess
efficaci
vaccin
vaccin
statu
anim
expos
brd
viral
pathogen
earli
stage
infect
prior
seroconvers
requir
repeat
sampl
addit
lower
initi
exposur
rate
viral
infect
field
set
combin
variat
strain
nucleotid
sequenc
short
period
viru
secret
highlight
requir
diva
approach
long
diagnost
window
strain
specif
potenti
approach
meet
need
base
applic
metabolom
identifi
metabolit
small
molecul
biolog
sampl
signatur
correl
provid
evid
immun
protect
metabolit
often
end
stage
product
biolog
process
therefor
provid
accur
represent
organ
homeostat
statu
time
sampl
metabolom
analysi
biofluid
provid
new
insight
understand
pathophysiolog
process
involv
diseas
establish
develop
diagnosi
whilst
metabolom
limit
applic
field
veterinari
research
sever
studi
demonstr
potenti
techniqu
predict
brd
diseas
outcom
differenti
stress
viral
infect
respons
characterist
immun
respons
follow
vaccin
studi
focus
specif
due
endemn
within
cattl
popul
absenc
clinic
symptom
still
predispos
anim
sever
bacteri
infect
due
small
genom
absenc
nonredund
protein
suitabl
remov
diva
vaccin
excel
model
assess
potenti
metabolom
establish
vaccin
statu
infect
anim
aim
current
studi
therefor
assess
perform
revers
phase
rp
hydrophob
interact
liquid
chromatographi
hilic
separ
method
ultra
perform
liquid
chromatographymass
spectrometri
uplcm
metabolom
profil
bovin
plasma
identifi
plasma
metabolom
marker
capabl
differenti
vaccin
nonvaccin
calv
follow
intranas
challeng
work
first
time
report
metabolom
respons
follow
challeng
demonstr
applic
metabolom
profil
may
help
overcom
current
limit
diva
diagnost
identifi
marker
capabl
differenti
vaccin
nonvaccin
anim
importantli
allow
develop
better
tool
assess
perform
vaccin
assess
clinic
find
anim
post
vaccin
challeng
report
detail
previous
briefli
anim
healthi
throughout
durat
studi
clinic
sign
diseas
vaccin
nonvaccin
studi
group
calv
sourc
respiratori
diseas
free
farm
histori
vaccin
brd
prior
commenc
vaccin
calv
test
seroposit
igg
residu
level
matern
deriv
immunoglobulin
keep
studi
employ
calv
age
commenc
vaccin
signific
differ
igg
observ
treatment
group
vaccin
rispov
result
signific
increas
igg
signific
increas
nonvaccin
control
follow
challeng
vaccin
calv
significantli
higher
plasma
igg
rel
nonvaccin
anim
challeng
igg
remain
elev
vaccin
anim
although
signific
differ
igg
level
observ
nonvaccin
anim
day
postinfect
pi
igg
elev
anim
rel
day
level
remain
anim
demonstr
elev
level
day
day
pi
signific
increas
lymphocyt
count
nonvaccin
anim
day
pi
signific
decreas
day
signific
variat
observ
vaccin
anim
signific
differ
neutrophil
count
studi
group
sampl
point
postinfect
howev
signific
p
tempor
variat
observ
decreas
day
nonvaccin
anim
increas
day
studi
group
day
pi
anim
per
group
prepar
gross
postmortem
analysi
two
anim
nonvaccin
group
show
gross
inflammatori
lesion
perivascular
cuf
consist
pneumonia
signific
gross
histolog
abnorm
detect
vaccin
calv
day
pi
postmortem
preliminari
metabolom
analysi
perform
select
suitabl
method
comprehens
profil
metabolit
within
bovin
plasma
rp
hilic
chromatograph
method
compar
use
day
pi
sampl
n
correspond
peak
viral
titr
despit
improv
resolut
poorli
retain
hydrophob
compound
elut
hilic
separ
increas
chromatograph
peak
correspond
plasma
deriv
compound
rel
blank
inject
observ
rp
acquir
profil
fig
rel
hilic
profil
fig
observ
differ
plasma
sampl
vaccin
nonvaccin
anim
within
chromatogram
profil
present
use
rp
fig
furthermor
upon
data
extract
process
metabolit
cv
qc
pool
increas
number
accur
mass
retent
time
pair
amrtp
observ
follow
rp
n
rel
hilic
n
separ
plasma
unsupervis
pca
analysi
plasma
profil
acquir
rpuplcm
result
clear
separ
studi
group
assess
principl
compon
pc
system
variat
within
dataset
illustr
fig
contrast
hilicuplcm
metabolom
profil
facilit
partial
separ
studi
group
base
pca
score
plot
system
variat
fig
due
small
number
chromatograph
peak
fewer
amrtp
poor
unsupervis
pca
separ
plasma
profil
acquir
follow
hilicuplcm
chromatographi
rpuplcm
select
method
choic
metabolom
profil
remain
studi
plasma
sampl
plasma
sampl
day
pi
extract
analys
combin
day
pi
data
multivari
analysi
mass
accuraci
retent
time
deviat
refer
compound
analysi
run
excel
tabl
within
marker
lynx
extract
paramet
respect
ensur
accur
peak
match
amrtp
n
cv
less
interrun
qualiti
control
plasma
pool
use
construct
pca
model
prefilt
amrtp
extract
raw
data
effect
challeng
metabolit
profil
anim
irrespect
vaccin
statu
illustr
unsupervis
pca
score
plot
fig
separ
pre
day
pi
challeng
sampl
day
pi
observ
greatest
separ
observ
day
preand
day
pi
postchalleng
stage
vaccin
nonvaccin
anim
differenti
vaccin
nonvaccin
anim
base
metabolit
profil
follow
challeng
investig
use
unsupervis
pca
supervis
oplsda
multivari
analysi
prior
challeng
metabolit
profil
variat
vaccin
nonvaccin
anim
low
evidenc
separ
day
fig
observ
pc
studi
progress
postchalleng
stage
variat
vaccin
nonvaccin
anim
metabolit
profil
increas
partial
separ
day
pi
fig
pc
clear
separ
day
fig
fig
fig
variat
respect
pc
oplsda
analysi
employ
select
marker
amrtp
could
discrimin
vaccin
nonvaccin
anim
postinfect
fig
illustr
oplsda
score
inset
splot
supervis
discrimin
analysi
plasma
metabolit
profil
infect
vaccin
nonvaccin
anim
day
p
respect
amount
variat
respons
differenti
anim
differ
vaccin
statu
model
gener
day
pi
respect
excel
fit
good
crossvalid
predict
oplsda
known
overfit
particularli
megavari
dataset
number
variabl
higher
sampl
size
employ
permut
fals
discoveri
rate
test
reduc
chanc
select
fals
posit
leaveoneout
cross
valid
perform
assess
perform
model
gener
briefli
technic
replic
singl
biolog
sampl
test
sampl
remov
remain
dataset
employ
gener
predict
oplsda
model
vaccin
vs
nonvaccin
predict
oplsda
model
employ
predict
vaccin
treatment
group
test
sampl
crossvalid
permeat
biolog
sampl
assess
treatment
classif
result
tabl
indic
biolog
replic
accur
classifi
respect
treatment
group
upon
cross
valid
predict
model
test
amrtp
contribut
class
discrimin
select
criterion
variabl
import
score
vip
score
oplsda
discrimin
analysi
amrtp
filter
select
fold
chang
fc
signific
differ
anova
bonferroni
posthoc
test
p
studi
group
final
select
amrtp
perform
assess
raw
mass
spectrometr
data
determin
good
peak
shape
consist
peak
intens
height
replic
inject
uniqu
potenti
marker
combin
oplsda
analysi
day
pi
day
pi
day
pi
day
pi
select
refin
remov
fragment
adduct
parent
ion
identif
select
panel
uniqu
amrtp
tabl
differenti
anim
differ
vaccin
statu
variou
timepoint
challeng
deconvolut
identifi
parent
ion
mass
adduct
low
energi
fragment
use
low
high
energi
data
function
respect
yield
parent
ion
element
composit
determin
nonparametr
mann
whitney
also
employ
select
panel
metabolit
day
pi
time
point
marker
attain
signific
level
within
threshold
compar
anova
fals
discoveri
rate
calcul
cv
filter
dataset
via
benjaminihochberg
procedur
threshold
select
marker
pass
threshold
met
select
criteria
vip
score
fc
select
potenti
marker
retent
time
accur
mass
potenti
marker
challeng
day
pi
shown
tabl
first
studi
report
potenti
differenti
infect
anim
differ
vaccin
statu
use
metabolom
profil
techniqu
diva
metabolom
previou
work
author
demonstr
metabolom
identifi
metabolit
associ
immun
respons
vaccin
current
studi
advanc
concept
appli
metabolom
analysi
plasma
identifi
uniqu
metabolit
marker
profil
capabl
distinguish
vaccin
nonvaccin
anim
follow
infect
calv
vaccin
rispov
infectionchalleng
demonstr
significantli
stimul
igg
postvaccin
respons
remain
elev
postchalleng
lung
histolog
haematolog
confirm
inoculum
employ
viral
challeng
suffici
induc
evid
respiratori
patholog
nonvaccin
anim
absenc
vaccin
anim
subsequ
challeng
prime
vaccin
anim
also
result
mainten
prechalleng
elev
igg
indic
respons
inoculum
absenc
respiratori
patholog
follow
preliminari
analysi
subset
sampl
day
pi
rpuplcm
analysi
demonstr
increas
capac
profil
bovin
plasma
metabolit
rel
hilicbas
chromatograph
separ
subsequ
use
extens
metabolom
plasma
profil
unsupervis
pca
analysi
acquir
metabolom
profil
preand
postchalleng
plasma
reveal
clear
distinguish
variat
plasma
metabolit
vaccin
nonvaccin
anim
consid
elev
igg
typic
occur
week
postchalleng
variat
plasma
metabolit
profil
earli
day
pi
illustr
capac
metabolom
profil
method
detect
chang
stimul
immun
respons
earli
postinfect
phase
supervis
multivari
discrimin
analysi
plasma
metabolom
profil
yield
potenti
metabolit
amrtp
significantli
differ
plasma
vaccin
compar
nonvaccin
anim
follow
challeng
follow
deconvolut
remov
adduct
fragment
ion
parent
metabolit
ion
identifi
shown
present
differ
level
within
plasma
vaccin
nonvaccin
anim
day
pi
despit
signific
differ
parent
ion
intens
treatment
group
day
pi
plasma
metabolit
profil
differ
vaccin
nonvaccin
anim
supervis
opslda
ident
parent
metabolit
reveal
via
databas
search
silco
fragment
spectral
match
diverg
plasma
metabolit
profil
previous
report
follow
vaccin
alter
metabolit
shown
associ
primari
secondari
immun
respons
vaccin
metabolom
profil
perform
studi
challeng
acquir
sampl
identifi
uniqu
panel
plasma
metabolit
differ
vaccin
nonvaccin
anim
significantli
involv
recognis
immun
respons
mechan
day
pi
increas
biliverdin
fc
bilirubin
fc
decreas
acid
fc
level
observ
plasma
nonvaccin
anim
biliverdin
degrad
heme
hemeoxygenas
reduc
bilirubin
bilirubin
reductas
exert
antiinflammatori
effect
demonstr
reduc
tumour
necrosi
factor
alpha
releas
lipopolysaccharidestimul
macrophag
acid
reactiv
oxygen
speci
scaveng
produc
microbiom
phagocyt
activ
rna
virus
result
increas
reactiv
oxygen
speci
releas
product
prooxid
cytokin
tumour
necrosi
factor
alpha
promot
iron
uptak
mononuclear
phagocyt
system
decreas
plasma
acid
level
concert
elev
biliverdin
bilirubin
level
via
action
nonvaccin
anim
day
pi
mayb
indic
acid
scaveng
reactiv
oxygen
speci
produc
phagocyt
increas
downstream
ro
product
cytokin
signal
fluctuat
level
number
bile
acid
acid
cholic
acid
ndgca
observ
plasma
anim
variou
stage
studi
acid
ndgca
found
significantli
increas
fc
respect
plasma
nonvaccin
anim
day
pi
respect
wherea
cholic
acid
significantli
higher
vaccin
anim
fc
day
pi
alter
plasma
bile
acid
profil
distinct
studi
phase
suggest
bile
acid
metabol
conjug
associ
differ
immun
respons
mechan
bile
acid
driven
farnesoid
x
receptor
activ
express
pulmonari
endotheli
cell
enabl
regulatori
immun
respons
demonstr
dendrit
cell
modul
natur
killer
tcell
inhibit
reduc
proinflammatori
osteopontin
product
reduc
lung
permeabl
suppress
leukocyt
movement
site
tissu
inflamm
transport
cell
ndgca
potent
farnesoid
x
receptor
activ
elev
ndgca
day
nonvaccin
anim
suggest
associ
switch
andor
suppress
innat
inflammatori
respons
toward
adapt
immun
respons
cholic
acid
primari
metabolit
cholesterol
found
significantli
increas
day
pi
vaccin
anim
cholesterol
compon
lymphocyt
lipid
raft
support
band
tcell
receptor
signal
revers
cholesterol
transport
associ
immunosuppress
via
reduct
band
tcell
receptor
signal
lymphocyt
activ
prolifer
elev
cholic
acid
may
indic
increas
cholesterol
metabol
via
revers
cholesterol
transport
prolifer
lymphocyt
downregul
secondari
immun
respons
viral
challeng
later
stage
infect
day
pi
lysophosphatidylcholin
produc
phosphatidylcholin
stimul
dendrit
cell
matur
action
gproteincoupl
receptor
abil
stimul
product
cell
indic
role
innatetoadapt
immun
respons
progress
plasma
level
six
lysophosphatidylcholin
deriv
significantli
upregul
fc
nonvaccin
anim
day
pi
significantli
higher
plasma
level
suggest
involv
system
immun
respons
primari
antigen
stimul
dendrit
cell
recruit
lymph
node
subsequ
dendrit
cell
driven
tcell
activ
decreas
plasma
peak
intens
enterolacton
fc
lignan
metabolit
form
rumin
action
colon
bacteria
secoisolariciresinol
diglucosid
observ
nonvaccin
anim
day
pi
enterolacton
cross
intestin
barrier
exert
antiinflammatori
function
suppress
nuclear
signal
tumour
necrosi
factor
alpha
product
releas
enterolacton
dietari
deriv
readili
replenish
upregul
period
high
demand
therefor
decreas
enterolacton
nonvaccin
anim
latter
stage
infect
day
postchalleng
may
reflect
metabol
induc
antiinflammatori
effect
associ
transit
acut
adapt
immun
respons
diagnost
perspect
plasma
metabolit
marker
found
alter
earli
stage
infect
prior
seroconvers
persist
later
stage
infect
particular
interest
hexahydrohippur
despit
show
significantli
alter
plasma
level
day
pi
remain
elev
vaccin
anim
fc
durat
studi
significantli
lower
level
nmethylhippur
acid
fc
higher
n
glycin
fc
also
observ
vaccin
calv
day
pi
n
glycin
nmethylhippur
acid
hexahydrohippur
form
action
glycin
nacyltransferas
cyclohexanecarboxycoa
benzoylcoa
produc
shikim
phenylalanin
metabol
signific
variat
plasma
level
phenylalanin
would
attribut
challeng
acylglycin
conjug
dietari
variat
elev
hexahydrohippur
n
glycin
level
may
consequ
increas
demand
coa
liver
due
need
free
coa
otherwis
sequest
cyclohexanecarboxycoa
increas
coa
demand
may
therefor
associ
increas
rate
band
tcell
prolifer
antibodi
product
follow
adapt
memori
respons
challeng
illustr
previous
postparent
immun
assess
hexahydrohippur
concentr
plasma
could
allow
differenti
vaccin
statu
infect
calv
wider
diagnost
window
observ
current
monitor
differ
igg
level
hexahydrohippur
occur
high
abund
plasma
offer
potenti
use
realist
marker
could
measur
use
onsit
base
test
method
conclus
studi
highlight
potenti
untarget
uplcm
metabolom
differenti
vaccin
status
viru
challeng
anim
ie
diva
metabolom
differenti
prechalleng
immun
statu
vaccin
nonvaccin
anim
result
diverg
plasma
metabolit
profil
follow
challeng
evid
earli
day
pi
increas
variat
time
post
challeng
metabolit
identifi
associ
immun
cell
regul
mechan
includ
tbcell
prolifer
phagocyt
activ
matur
wide
diagnost
window
hexahydrohippur
combin
metabolit
marker
alter
distinct
time
period
associ
specif
immun
respons
mechan
eg
lysopc
biliverdin
bilirubin
acid
could
find
applic
stage
infect
effect
effort
reflect
larg
magnitud
foldchang
low
intragroup
variat
statist
significantli
metabolit
identifi
day
pi
similar
cytokin
profil
metabolom
base
diagnost
unlik
match
pathogen
specif
molecular
serolog
test
instead
provid
greater
inform
physiolog
health
statu
futur
diseas
diagnost
potenti
employ
multipl
method
improv
diseas
manag
decis
limit
studi
mani
biomark
discoveri
investig
involv
larg
bovin
anim
small
cohort
size
ie
n
per
group
n
day
pi
incorpor
effect
experiment
group
potenti
may
impact
find
result
analysi
accur
translat
observ
within
wider
variabl
herd
popul
mitig
issu
anim
extens
screen
regard
health
matern
antibodi
statu
prior
studi
group
inclus
postmetabolom
profil
stringent
metabolit
select
criteria
fc
p
vip
score
fals
discoveri
rate
appli
select
robust
metabolit
marker
candid
investig
use
larger
comprehens
sampl
set
differ
sex
breed
age
anim
altern
rout
vaccin
vaccin
failur
degrad
immunosuppress
challeng
multipl
pathogen
may
determin
panel
fingerprint
metabolit
greater
diagnost
specif
number
unidentifi
marker
show
promis
express
profil
metabolom
still
rel
new
field
lack
level
databas
curat
compar
genom
proteom
marker
identif
marker
may
identifi
futur
studi
requir
expand
upon
initi
proofofconcept
determin
observ
diva
metabolit
marker
robust
importantli
studi
identifi
potenti
marker
would
also
benefit
screen
assess
new
vaccin
formul
allow
identif
trail
indic
protect
immun
respons
hplc
grade
aceton
analyt
standard
purchas
sigma
aldrich
dorset
uk
lcm
grade
acetonitril
water
methanol
chloroform
purchas
fisher
scientif
loughborough
uk
anim
studi
carri
accord
uk
anim
scientif
procedur
act
approv
agrifood
bioscienc
institut
northern
ireland
ethic
review
committe
calv
vaccin
rispov
previous
report
briefli
male
holstein
friesian
calv
age
week
sourc
commerci
farm
histori
prior
respiratori
diseas
outbreak
calv
prior
vaccin
brd
clinic
examin
declar
fit
studi
day
name
veterinari
surgeon
clave
divid
two
studi
group
n
assign
nonvaccin
vaccin
calv
vaccin
calv
treat
pfizer
rispov
intranas
vaccin
design
vaccin
anim
per
manufactur
instruct
nonvaccin
calv
treat
empti
poli
lacticcoglycol
acid
nanoparticl
design
nonvaccin
prepar
use
standard
doubl
emulsif
solvent
evapor
techniqu
wow
calv
receiv
two
dosag
vaccin
formul
day
prior
intranas
challeng
postinfect
pi
inocul
ml
viru
suspens
tcid
ml
per
nostril
calv
screen
weekli
follow
vaccin
day
infect
pi
presenc
igg
blood
serum
use
kit
boehring
ingelheim
svanovir
uppsala
sweden
per
manufactur
instruct
day
pi
anim
per
group
sacrif
viral
isol
histolog
sampl
blood
sampl
drawn
via
jugular
venepunctur
day
pi
plastic
edta
vacuett
tube
greiner
bioon
stroudwat
uk
process
random
platelet
poor
plasma
via
doubl
centrifug
method
optim
metabolom
analysi
within
hour
initi
blood
draw
plasma
store
prior
use
sampl
process
order
random
negat
process
bia
sampl
metabolit
profil
plasma
ad
ml
ice
cold
aceton
vortex
sec
place
ice
min
sampl
deprotein
centrifug
min
ml
supernat
remov
dri
nitrogen
min
use
turbovap
lv
calip
life
scienc
hopkinton
usa
result
residu
reconstitut
ultrapur
h
liquidliquid
extract
lipid
perform
addit
icecold
methanol
chloroform
vv
vortex
sec
follow
centrifug
min
liquidliquid
extract
repeat
centrifug
aqueou
layer
remov
dri
nitrogen
residu
reconstitut
ultrapur
h
filter
centrifug
use
costar
spinx
centrifug
tube
filter
min
plasma
ad
well
ostro
protein
precipit
phospholipid
remov
plate
water
corpor
milford
usa
formic
acidacetonitril
vv
ad
sampl
well
plate
shaken
sec
extract
metabolit
drawn
vacuum
well
ml
collect
plate
rpuplcm
analysi
perform
use
acquiti
uplc
system
coupl
xevo
qtof
water
corpor
milford
usa
test
mix
acetominophen
sulfaguanidin
sulfadimethoxin
valtyrv
verapmil
terfenadin
leucineenkephalin
reserpin
erythromycin
inject
ensur
calibr
mass
spectromet
mass
accuraci
uplc
perform
prior
analysi
pool
sampl
compris
aliquot
studi
sampl
inject
time
start
run
column
condit
intermitt
throughout
run
valid
instrument
perform
runord
sampl
enter
mass
spectromet
construct
use
random
sampl
list
compris
technic
replic
per
biolog
sampl
sampl
inject
analysi
run
prepar
sampl
extract
inject
onto
acquiti
uplc
column
mm
x
mm
id
water
corpor
milford
usa
column
autosampl
temperatur
maintain
respect
chromatograph
separ
carri
flow
rate
mobil
phase
consist
formic
acid
formic
acid
b
elut
gradient
follow
min
isocrat
b
min
linear
gradient
form
b
min
isocrat
b
final
min
linear
gradient
b
mass
spectrometri
perform
positiveion
mode
esi
capillari
voltag
set
v
sampl
cone
voltag
desolv
cone
ga
flow
set
lh
lh
respect
sourc
desolv
temperatur
respect
leucin
enkephalin
mh
da
mh
da
use
accur
lockmass
calibr
data
acquisit
lockmass
acquisit
set
sec
scan
time
sec
interv
scan
averag
mass
window
centroid
data
acquir
posit
mode
use
resolut
mode
collis
energi
appli
function
ramp
ev
ev
hilicuplcmsm
analysi
test
mix
cytosin
oacetyllcarnitin
lvalin
pool
sampl
compris
aliquot
studi
sampl
inject
time
start
run
column
condit
intermitt
throughout
run
valid
instrument
perform
runord
sampl
enter
mass
spectromet
construct
use
random
sampl
list
compris
technic
replic
per
biolog
sampl
sampl
inject
analysi
run
prepar
sampl
extract
inject
onto
acquiti
uplc
beh
hilic
column
mm
x
mm
id
water
corpor
milford
usa
column
autosampl
temperatur
maintain
respect
chromatograph
separ
carri
flow
rate
mobil
phase
consist
mm
ammonium
format
ph
acetonitril
formic
acid
b
elut
gradient
follow
min
isocrat
min
linear
gradient
form
min
linear
gradient
min
isocrat
min
linear
gradient
min
isocrat
mass
spectrometri
perform
use
water
xevo
qtof
milford
oper
positiveion
mode
esi
capillari
voltag
set
sampl
cone
voltag
desolv
cone
ga
flow
set
respect
sourc
desolv
temperatur
respect
leucin
enkephalin
use
accur
lockmass
calibr
data
acquisit
acquisit
set
rpuplcm
analysi
centroid
data
acquir
posit
mode
use
resolut
mode
collis
energi
appli
function
ramp
total
ion
count
tic
chromatogram
spectra
acquir
masslynx
version
water
corpor
milford
usa
centroid
format
metabolit
data
process
use
markerlynx
softwar
markerlynx
method
data
extract
deconvolut
follow
ion
extract
function
data
use
peak
detect
analysi
retent
time
window
mass
rang
xic
window
data
collect
apex
peak
track
paramet
set
automat
smooth
data
collect
paramet
consist
intens
threshold
count
mass
window
retent
time
window
nois
elimin
level
appli
isotop
remov
peak
height
extract
ion
normal
total
peak
height
extract
ion
standard
total
ion
count
result
export
csv
format
two
dimension
data
tabl
row
column
respect
repres
analys
sampl
rel
normal
peak
height
detect
mass
spectrometr
signal
ie
accur
mass
mz
retent
time
min
pair
amrtp
extract
process
data
submit
downstream
multivari
statist
analysi
metabolit
marker
select
found
supplementari
data
tabl
tempor
chang
antibodi
titr
analys
use
twotail
pair
ttest
signific
differ
treatment
group
sampl
stage
assess
use
twotail
heteroscedast
ttest
simcap
version
umetr
sweden
use
multivari
metabolit
marker
select
dataset
prefilt
exclud
amrtp
coeffici
variat
greater
interrun
qualiti
control
pool
gener
equal
aliquot
extract
sampl
inject
intermitt
throughout
analysi
run
centroid
data
pareto
scale
analys
unsupervis
principl
compon
analysi
pca
supervis
discriminatori
analysi
orthogon
project
latent
structuresdiscrimin
analysi
oplsda
unsupervis
pca
model
gener
sampl
day
reveal
potenti
relationship
treatment
group
supervis
analysi
oplsda
perform
reveal
potenti
marker
respons
treatment
vaccin
calv
compar
nonvaccin
calv
sampl
day
robust
final
oplsda
discrimin
model
assess
set
predict
model
case
data
known
treatment
use
predict
remain
unknown
treatment
signific
identifi
marker
time
point
determin
use
anova
bonferroni
posthoc
test
nonparametr
mann
whitney
day
pi
time
point
element
composit
select
parent
compound
determin
masslynx
use
posit
neg
mode
data
mass
uncertainti
set
mda
odd
even
electron
state
carbon
isotop
filter
element
includ
c
h
n
p
applic
na
k
adduct
element
composit
determin
respect
element
includ
analysi
paramet
element
composit
search
pubchem
chemspid
onlin
databas
possibl
function
fragment
match
metlin
hmdb
massbank
databas
fragment
spectra
analyt
question
avail
silico
fragment
perform
use
metfrag
function
fragment
data
valid
potenti
silico
fragment
identifi
compound
valid
use
mass
spectrum
retent
time
rel
authent
analyt
standard
analys
ident
experiment
condit
fig
pool
plasma
sampl
individu
analyt
standard
analys
ident
uplc
mass
spectrometr
run
condit
util
previous
metabolit
ident
confirm
match
retent
time
function
function
spectra
includ
low
high
energi
fragment
adduct
put
annot
acquir
compound
spectral
similar
public
spectral
librari
metlin
hmcb
massbank
tabl
crossvalid
oplsda
model
leaveoneout
loo
cross
valid
perform
assess
perform
model
gener
technic
replic
singl
biolog
sampl
remov
oplsda
model
contain
remain
biolog
technic
replic
employ
predict
class
represent
xlsx
tabl
select
amrtp
plasma
metabolom
marker
respons
challeng
vaccin
nonvaccin
anim
combin
list
amrtp
select
use
oplsda
day
infect
filter
exclud
p
fc
vip
score
xlsx
tabl
process
raw
data
employ
downstream
metabolom
analysi
markerlynx
employ
data
extract
process
amrtp
level
report
peak
height
